Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

2018625 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet Respiratory Medicine

Volume 7, Issue 2, pp. 154-162

Field-Weighted Citation Impact: 58.83